Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,730 Cr
verified against source
Revenue YoY
9%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Cipla delivered a solid Q4 FY25 with revenue of INR 6,730 crore (+9% YoY) and EBITDA margin of 22.8% (+150bps YoY), driven by strong performance across One India (+8% YoY), North America ($221M quarterly revenue), and EMU (+16% YoY). PAT stood at INR 1,222 crore. The company guided FY26 EBITDA margin of 23.5%-24.5%, reflecting confidence despite generic Revlimid exclusivity loss. Key growth drivers include respiratory pipeline (Advair launch in FY26, six respiratory ANDAs filed), peptide launches (two to three in FY26), and Nano Paclitaxel/Nilotinib approvals. One India chronic mix improved to 61.5%. Risk: Generic Revlimid compression could pressure U.S. revenue and margins in coming quarters.
Colored figures show movement against the previous available record.
Guidance to track
- Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss.
- Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
- Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.
- Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.
Risks flagged
- Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.
- While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.
- Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.
- Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory.
Key quotes
- Our One India business surpassed the landmark of INR 11,000 crore revenues, reflecting our strength in the domestic market.
- Our leading inhalation brand became the first brand in the history of IPM to cross INR 9,000,000,000 crore reaffirming its position as a market leader.
- Our outlook for projected EBITDA margin is in the range of about 23.5%-24.5%.
Research modules